Lastly, patients with pancreas-sufficient cystic fibrosis are at risk of acute pancreatitis, which can be reduced by cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, such as with Ivacaftor or Tezacaftor [94]. This evidence concerns the gene CFTR and cystic fibrosis.